BCAL Diagnostics Limited (BDX.AX)
ASX - ASX Delayed price. Currency in AUD
Add to watchlist
As of 04:10PM AEST. Market open.
| Previous close | 0.0950 |
| Open | 0.0960 |
| Bid | 0.0950 x N/A |
| Ask | 0.0970 x N/A |
| Day's range | 0.0960 - 0.0970 |
| 52-week range | 0.0700 - 0.2100 |
| Volume | |
| Avg. volume | 242,631 |
| Market cap | 24.473M |
| Beta (5Y monthly) | 0.27 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | N/A |
| Earnings date | N/A |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | N/A |
- PR Newswire
BCAL Findings Presented at 2023 ASCO Annual Meeting
BCAL Diagnostics Limited (ASX:BDX) (BCAL or Company) today announced the presentation of data demonstrating the potential for detection of early breast cancer using a plasma lipidomic biomarker signature. BCAL is developing a non-invasive blood screening test that is intended to be used alongside breast cancer screening methods, such as mammography. The poster, "Lipidomic Signature From Plasma to Detect Localised Breast Cancer," was presented at the 2023 ASCO Annual Meeting (Chicago, 2-6 June 20
© 2024 Yahoo. All rights reserved.